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ABSTRACT 
Introduction. Fabry disease is a rare metabolic 
disorder caused by the genetic deficiency of the 
lysosomal hydrolase alpha-galactosidase A, located 
on chromosome X. Females with the defective gene 
are more than carriers and can develop a wide 
range of symptoms. Nevertheless, disease symp-
toms generally occur later and are less severe in 
women than in men. The enzyme deficiency mani-
fests as a glycosphingolipidosis with progressive 
accumulation of glycosphingolipids and deposit 
of inclusion bodies in lysosomes giving a myelin-
like appearance.
Patients and Methods. Records of renal biopsies 
performed on adults from 1st January 2008 to 31st 
August 2011, were retrospectively examined at the 
Renal Pathology Laboratory. We retrieved biopsies 
diagnosed with Fabry disease and reviewed clinical 
and laboratory data and pathology findings.
Results. Four female patients with a mean age of 
49.3±4.5 (44-55) years were identified. The mean 
proteinuria was 0.75±0.3 g/24h (0.4-1.2) and esti-
mated glomerular filtration rate (CKD EPI equation) 
was 71±15.7 ml/min/1.73m2 (48-83). Three patients 
experienced extra-renal organ involvement (cerebro-
vascular, cardiac, dermatologic, ophthalmologic and 
thyroid) with distinct severity degrees. Leukocyte 
α-GAL A activity was below normal range in the four 
cases but plasma and urinary enzymatic activity was 
normal.
Light microscopy showed predominant vacuolisa-
tion of the podocyte cytoplasm and darkly staining 
granular inclusions on paraffin and plastic-embedded 
semi-thin sections. Electron microscopy showed in 
three patients the characteristic myelin-like inclusions 
in the podocyte cytoplasm and also focal podocyte 
foot process effacement. In one case the inclusions 
were also present in parietal glomerular cells, endothe-
lial cells of peritubular capillary and arterioles.
Conclusion. Clinical signs and symptoms are varied 
and can be severe among heterozygous females with 
Fabry disease. Intracellular accumulation of gly-
cosphingolipids is a characteristic histologic finding 
of Fabry nephropathy. Since this disease is a poten-
tially treatable condition, its early identification is 
imperative. We should consider it in the differential 
diagnosis of any patient presenting with proteinuria 
and/or chronic kidney disease, especially if there is 
a family history of kidney disease.
Key-Words:
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INTRODUCTION 
Fabry disease (FD) is a progressive, X-linked inher-
ited disorder of glycosphingolipid metabolism due 
to deficient or absent lysosomal α-galactosidase A 
(α-GAL A) activity. This results in progressive accu-
mulation of globotriaosylceramide (Gb3 or GL-3) and 
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related glycosphingolipids within lysosomes in a 
variety of cell types, including capillary endothelial 
cells, renal, cardiac and nerve cells1.
The incidence of Fabry disease has been estimated 
to be 1:117,000 overall births2. The age of symptom 
onset and the age of diagnosis tend to be approxi-
mately 10 years later in females than males3. There 
is often significant delay in the diagnosis4.
Phenotype differences are due in part to random 
X-chromosome inactivation, resulting in considerable 
variability in α-GAL A activity among carriers and 
within one carrier individual among various tissues 
or regions of a single tissue4.
The classical phenotype presents with early der-
matologic, ophthalmologic, and peripheral nervous 
system involvement. Renal, cardiac and cerebrovas-
cular complications are major causes of morbidity 
and mortality in adults1.
Renal impairment often begins with microalbu-
minuria and proteinuria in the second to third 
decade of life. Isosthenuria accompanied by altera-
tions in tubular reabsorption, secretion and excre-
tion also develops1. By adulthood, renal failure 
frequently becomes a major complication of Fabry 
disease, with more than half of males eventually 
developing advanced renal failure or end-stage renal 
disease (ESRD)5.
Heterozygous female individuals can develop a 
wide range of symptoms, ranging from asymptomatic 
to overt disease6. The majority of females have slowly 
progressive kidney disease, but a smaller subset 
seem to be more seriously affected with progression 
to ESRD at the same median age as men7.
Classically, renal lesions result from Gb3 deposi-
tion in the lysosomes of podocytes, glomerular 
endothelial, parietal epithelial, mesangial and inter-
stitial cells that may lead to progressive microvas-
cular dysfunction, occlusion and ischaemia, with 
subsequent development of segmental and global 
glomerular sclerosis, tubular atrophy and interstitial 
fibrosis8-10. Podocyte injury might correlate directly 
with proteinuria and play a pivotal role in the devel-
opment and progression of Fabry nephropathy11. 
Glycosphingolipid storage also occurs in the epithe-
lium of the loop of Henle and the distal tubules, 
and in the endothelial and smooth muscle cells of 
the renal arterioles1.
Kidney biopsy may be useful as a baseline assess-
ment and in patients with atypical presentations, includ-
ing a repeat kidney biopsy when the disease is progress-
ing despite therapy1. In some cases, females can develop 
the same kidney histopathology as males8,12,13.
The aim of this study is to review the clinico-
pathological findings of females with Fabry disease, 
whose renal biopsies were analysed in a single neph-
ropathology laboratory.
PATIENTS AND METHODS 
Four renal biopsies performed on four adult 
females and analysed at our institution from 1st Janu-
ary 2008 to 31st August 2011 were retrospectively 
examined.
We recorded the following data from each patient: 
age, gender, race, indication for renal biopsy (clinical 
syndrome), clinical manifestations in other organs, 
GLA gene mutation, plasma and leukocyte α-GAL A 
levels and urinary activity measurements.
Renal biopsy specimens were stained and analysed 
by light microscopy (LM), immunofluorescence (IMF) 
and electron microscopy (EM). Routine LM examina-
tion was performed on haematoxylin and eosin (HE), 
periodic acid-Schiff (PAS), Jones methenamine silver 
(SM), and trichrome stains (TR). Histological findings 
were scored by LM, with respect to glomerular and 
interstitial changes as 0, none; 1, mild (<25%); 2, 
moderate (25-50%); and 3, severe change (>50%)8. 
Vascular changes were analysed for intimal thicken-
ing and hyalinosis using the same scoring system.
We reviewed the semi-thin toluidine blue-stain 
sections that were prepared as survey sections for 
electron microscopy.
All specimens were studied by IMF using anti-
immunoglobulin (A, G and M), anti-C3, C4, C1q of 
complement and anti-albumin antibodies.
Electron microscopy images were reviewed in all 
cases.
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RESULTS 
Clinical findings 
We retrospectively identified four female patients 
with Fabry disease in our renal biopsy files, and 
their clinical and laboratory data are summarised in 
Table I.
All patients were Caucasian, ranging in age from 
44 to 55 years (mean 49.3±4.5). Estimated glom-
erular filtration rate (CKD EPI equation) was 71±15.7 
ml/min/1.73m2 (48-83). Three patients with a mean 
age of 39.3±6.0 (33-45) years were diagnosed with 
hypertension and, in these cases, 24-hour urine 
total protein (mean 0.75±0.34 g/24h) was measured 
while on treatment with angiotensin converting 
enzyme inhibitors and/or angiotensin receptor 
blockers.
Two patients were sisters (patients 1 and 2) and 
all had at least one case of first-degree family history 
of renal disease.
The indications for renal biopsy were non-
nephrotic proteinuria in three patients and chronic 
renal failure with proteinuria in the other.
In three cases the diagnosis was established by 
biochemical and genetic studies prior to renal biopsy. 
Skin biopsy of angiokeratomas performed in our 
nephropathology centre (Fig. 1) allowed the diagnosis 
in one case (patient 3).
All the females had leukocyte α-GAL A activity 
below normal range but plasma and urinary enzymatic 
activity was normal.
Clinical manifestations were provided by the 
patients' physicians and are shown in Table II. Car-
diovascular involvement was exhibited as hyperten-
sion in three patients and also left ventricular hyper-
trophy in other case. Cryptogenic ischaemic stroke 
occurred in one patient at the age of 38 years. 
Ophthalmologic, cutaneous lesions, thyroid dysfunc-
tion and peripheral neuropathic pain were present 
in one patient. Finally, in one case the only mani-
festation was non-nephrotic proteinuria.
Light microscopy 
On average, 10±1.6 (range 8-12) glomeruli were 
present for light microscopic assessment, and 2.8±1.3 
Figure 1
Electron microscopy of skin biopsy (patient 3) of a small superficial 
angioma showing lysosomal inclusion with myelin-like figures within 
endothelial cells and capillary lumen).
Table I























1 49 0.9 75 0.4 20 10 8 Arg112His
2 55 0.8 83 0.6 2 5 No data Arg112His
3 44 0.9 78 0.8 1.9 6 No data Pro265Arg
4 49 1.3 48 1.2 27 6 2.9 ΔGlu358
* Reference range: 36-80 nmol/h/mg protein
** Reference range: 6-19 nmol/h/mL plasma
*** Reference range: <25 μmmol creat
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Table II
Clinical manifestations in female Fabry disease patients
Patient Family history Kidney Heart Eyes Skin  Nervous System Other
1




– – – – –
2




hypertension – hypohidrosis headache breast cancer















Brother died of CKD and 
renal transplantation 
Mother died of sudden death 































1 8 0/3 0/8 2/0/0/0 1/3 0/3 0/3 0/3 0/3
2 12 1/3 2/12 1/0/0/0 0/3 0/3 0/3 1/3 1/3
3 10 0/3 0 /10 3/2/1/1 1/3 0/3 0/3 0/3 0/3
4 10 0/3 1/10 2/0/0/1 1/3 1/3 0/3 3/3 2/3
[Score findings: 0, none; 1, mild (<25%); 2, moderate (25-50%); and 3, severe change (>50%)].
* p – podocytes, pg – parietal glomerular, pc – peritubular capillary, endothelial arteriolar cells
A B
Figure 2
Light microscopy in Fabry disease
(A) Renal biopsy of patient 4 with a glomerulus showing hypertrophic glomerular podocytes distended with foamy appearing vacuoles (PAS stain; mag-
nification, x400)
(B) Renal biopsy of patient 3 with a glomerulus showing extensive inclusion bodies of glycolipid in podocytes and parietal cells (arrows; toluidine blue 
stain; magnification, x 400)
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(range 1-4) glomeruli were examined on toluidine 
blue-stained semi-thin sections.
Renal pathology from light microscopy is described 
in Table III.
LM showed in all patients varying degrees of 
hypertrophic glomerular visceral epithelial cells dis-
tended with foamy appearing vacuoles (Fig. 2A), 
corresponding to extracted Gb3 deposits. There were 
also vacuoles in parietal glomerular, endothelial cells 
of peritubular capillary and arterioles in patient 3.
In one biopsy there was mild mesangial widening. 
In the tubulo-interstitial compartment, two patients 
had mild interstitial fibrosis, a chronic inflammatory 
infiltrate and tubular atrophy (less than 5%). Glomerular 
sclerosis (segmental or global) was not observed.
Vascular involvement was observed in two patients: 
arteriolar thickening, hyalinosis and elastic duplica-
tion, which led to the initial histological diagnosis 
of nephroangiosclerosis in one of the cases. The 
female patient with diabetes mellitus type 2 showed 
no lesions of diabetic nephropathy.
Semi-thin sections with toluidine blue showed fine 
but darkly staining granular inclusions (Fig. 2B) in 
varying degrees in the cytoplasm of podocytes in all 
patients. The most prominent location of the inclu-
sions was in podocytes but in two cases (patients 
3 and 4) it was present in peritubular capillary, 
glomerular endothelial and vascular intimal cells.
On frozen sections under polarised light, the gly-
cosphingolipids showed birefringence and autofluo-
rescence (Fig. 3).
Immunofluorescence was negative in all cases 
(including albumin and Ig G in the diabetic 
female).
Electron microscopy 
All the biopsies were analysed by electron 
microscopy.
In three specimens, podocyte inclusions that varied 
from granular to concentric lamellated were demon-
strated (Fig. 4) and in one biopsy it was also found 
on peritubular capillaries, parietal glomerular cells and 
arterial endothelial cells. Inclusions were surrounded 
by a single unit membrane, indicating their location 
in lysosomes. Areas of focal fusion of podocyte foot 
processes were present in three biopsies. No lesions 
were found in dense membrane of the glomeruli.
Unfortunately in one patient there was no sample 
for electron microscopy. The diagnosis of Fabry 
Clinical and pathological findings in women with Fabry disease
Figure 3
Light microscopy with polarised light (patient 3) showing glycosphingolip-
ids within a glomeruli that are birefrigent and exhibit autofluorescence 
(magnification, x 400)
Figure 4
Electron microscopy in renal biopsy of patient 1. Accumulation of storage 
material, with the appearance of lamellated membrane structures is dem-
onstrated in the secondary lysosomes of podocytes. There is focal foot 
process effacement (arrow).
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disease was made afterwards with identification of 
GLA mutation.
DISCUSSION 
In this case series of heterozygous females, clinical 
signs and symptoms varied widely. This phenotypic 
heterogeneity is thought to be partly due to lyonisa-
tion, a process whereby one copy of the X-chromo-
some is randomly inactivated in all cells of the female 
embryo1. Therefore, heterozygous females are essen-
tially a mosaic of normal and mutant cells in varying 
proportions21.
The degree of symptoms depends on the residual 
enzymatic activity of α-GAL A: females can have 
anywhere from near-normal levels to no active 
enzyme1. Of the 1077 females enrolled in the Fabry 
Registry, 69.4% had symptoms and signs of FD and 
twenty percent experienced major cerebrovascular, 
cardiac, or renal events at a median age of 46 
years5.
One female of our case series suffered an ischae-
mic stroke at the age of 38 years and on light 
microscopy, vascular abnormalities of severe hyper-
tension superimposed on the changes of FD were 
observed. There is a high prevalence of hypertension, 
cardiac disease and renal disease in patients who 
have had a stroke in the context of FD22. Data from 
the Fabry Registry22 and the Fabry Outcome Survey23 
have shown that the majority of strokes in FD are 
due to small vessel events. In a large cohort of young 
Portuguese patients the prevalence of GLA missense 
mutations was 3.8% in patients with cryptogenic 
stroke, and these mutations were associated with 
residual α-galactosidase activity levels much higher 
than those observed in classically affected Fabry 
patients14.
Incidental findings of corneal opacity by ophthal-
mologists can be another sign of FD. Corneal changes 
(cornea verticillata), rarely disturbing visual acuity, 
are frequently encountered in case series1 and was 
detected in one of our patients. Hearing loss has 
also been reported1,15.
In a small study, subclinical hypothyroidism was 
found in 36.4% of the patients16. Hypothyroidism 
was detected in one of our four cases. Faggiano et 
al. consider that endocrine work-up should be rec-
ommended in all patients suffering from FD17.
Proteinuria and CKD are important manifestations 
of Fabry disease7. All the female patients had pro-
teinuria and only one had moderate renal function 
impairment.
According to some authors, proteinuria and/or a 
reduced glomerular filtration rate may be found in 
40% of adult females7,18. Proteinuria was recently 
shown to be an important risk factor for progression 
of kidney dysfunction in Fabry disease19,20 with a 
much greater predictive value for men than women20. 
Deegan et al. found that proteinuria was not associ-
ated with a more rapid decline in GFR in females18.
An international effort has been mounted to create 
a standardised scoring system of the extent and 
severity of renal involvement, supporting the role of 
kidney biopsy in the baseline evaluation of Fabry 
nephropathy. This International Study Group consid-
ered that optimal slides for scoring should ideally 
include >10 glomeruli for light microscopic assess-
ment, and at least 3 glomeruli for semi-thin section 
scoring8. Renal specimens of our study contained a 
mean glomeruli number of 10±1.6 (range 8-12) pres-
ent for light microscopy and 2.8±1.3 (range 1-4) on 
toluidine blue-stained semi-thin sections.
Vacuolisation of podocytes and epithelial cells is 
a characteristic histological finding8. Glomerular pari-
etal epithelial cells are particularly involved in females 
with severe GLA gene mutations13 and this was found 
in patient 3 that had serious extra-renal manifesta-
tions of FD.
Fogo et al. found that arteriolar hyalinosis was simi-
lar in both genders, but females had significantly more 
arterial hyalinosis which was probably related to their 
significantly higher age8. We detected mild and severe 
arteriolar hyalinosis, respectively, in two biopsies.
Although mild interstitial fibrosis and tubular atro-
phy was found in only half of our patients, it should 
be emphasised that chronic glomerular and interstitial 
damage develops early in the course of Fabry disease, 
and the absence of typical clinical signs of CKD does 
not rule out Fabry nephropathy8. Our results are in 
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agreement with previous series of Fabry patients, 
showing histological changes before renal function 
is decreased. Renal biopsy in female patients with 
FD may therefore be important for establishing the 
diagnosis and characterisation of renal lesions.
During the study, it became clear to us that his-
tological findings suggestive of Fabry nephropathy 
(e.g. vacuolisation) may be missed on routine his-
tological sections unless there is a strong clinical 
suspicion. However, semi-thin sections are best for 
characterising podocyte Gb3 inclusions8.
Cellular inclusions of Gb3 within lysosomes have 
been described by various names, including zebra 
bodies and myelin figures, according to different 
morphologies of their pattern of lamellation. Podo-
cytes and distal tubular epithelial cells have been 
described as containing the highest concentrations 
of Gb324. In some cell types, inclusions appear as 
small, dark, dense-beaded granules; in others, they 
appear as larger complex laminated bodies24, as 
seen in this case series.
Noteworthy is that none of our patients had an 
history of taking medications known to cause Fabry-
like morphologic changes, such as chloroquine, amio-
darone, or aminoglycosides25-27.
Immunofluorescence was negative in all cases. 
According to literature, routine immunofluorescence 
microscopy is usually negative but in glomeruli with 
advanced lesions, immunoglobulin M, A, and comple-
ment components (C3 and C1q) may be detectable 
in capillary walls and mesangial regions showing a 
segmental distribution and granular pattern24.
In symptomatic individuals, the diagnosis of FD 
can be established on the basis of low activity of 
α-GAL A in plasma, leukocytes or cultured skin fibro-
blasts28. There is significant overlap in the α-GAL A 
activity levels of carrier females and the general 
population; thus, α-GAL A activity may not reliably 
distinguish the affected (carrier) from unaffected (non-
carrier) women. As shown in this series, females had 
a normal amount of plasma α-GAL A enzyme activity 
and still carried the defective gene.
For females with normal to low-normal α-GAL A, 
a genetic test is needed for accurate diagnosis15.
Mutation subtypes of FD may have impact on 
disease progression9. The mutation Arg112His dem-
onstrated in patients 1 and 2 is predominantly asso-
ciated with residual enzyme activity and a mild variant 
phenotype of FD29 which is consistent with our clini-
cal and histological findings.
There are several limitations when analysing our 
data, especially in rare diseases where the limited num-
ber of cases may not be representative of the Fabry 
female population. The prevalence of CKD and ESRD 
in the general population is much higher than in Fabry 
disease and, particularly in patients carrying GLA muta-
tions associated with significant residual enzyme activ-
ity, it should be noted that the cause of CKD may not 
always be a consequence of Fabry disease.
The diagnosis of Fabry disease among patients 
without a positive family history has been a chal-
lenge to nephrologists and since Fabry disease is a 
potentially treatable condition it is imperative to 
consider it in the differential diagnosis of any patient 
presenting with proteinuria and/or chronic kidney 
disease, especially if there is a family history of 
kidney disease30.
CONCLUSION 
Clinical signs and symptoms are varied and can 
be severe among heterozygous females with Fabry 
disease. Histological renal findings are notorious even 
in women with little clinical involvement – myelin-like 
structures were found within lysosomes in many 
renal cells. Glomerular sclerosis and tubulointerstitial 
fibrosis are minimal in females with no clinical expres-
sion of renal disease.
Fabry disease nephropathy should be considered 
for diagnosis of any patient presenting with CKD, 
especially in those with proteinuria and family history 
of renal disease.
This study should raise the awareness of this rare 
disease among nephrologists and other specialists 
that are likely to encounter unrecognised Fabry 
female patients to improve early diagnosis.
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